Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

Abstract Background The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS risk groups predict the likelihood of distant recurrence and have recentl...

Full description

Bibliographic Details
Main Authors: Gulisa Turashvili, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis, Hannah Y. Wen
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
Breast cancer
Estrogen receptor positive
Early stage
21-gene recurrence score assay
Low risk
Locoregional recurrence
Online Access:http://link.springer.com/article/10.1186/s12885-017-3985-y

Internet

http://link.springer.com/article/10.1186/s12885-017-3985-y

Similar Items